[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100501743":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":27,"locations":35,"responsibleParty":52,"collaborators":56,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":30,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":30,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":38,"whyStopped":30,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"University of Melbourne","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Gefapixant treatment","EXPERIMENTAL","Participants will asked to take an oral tablet containing 45mg Gefapixant twice daily (BID).",[13],"Drug: Gefapixant",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Gefapixant","Purinergic (P2X3) Receptor antagonist. Film-coated tablet taken orally.",[9],[21],"Merck (MK)-7264",[23],{"name":24,"affiliation":25,"role":26},"Stuart B Mazzone, PhD","+61383446457","PRINCIPAL_INVESTIGATOR",[28,32],{"name":24,"role":29,"phone":25,"phoneExt":30,"email":31},"CONTACT",null,"stuart.mazzone@unimelb.edu.au",{"name":33,"role":29,"phone":25,"phoneExt":30,"email":34},"Tara G Bautista, PhD","tara.bautista@unimelb.edu.au",[36],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"The University of Melbourne","RECRUITING","Parkville","Victoria","3010","Australia","AU",{"type":45,"coordinates":46},"Point",[47,48],144.95,-37.78333,{"lat":48,"lon":47},[51],{"name":24,"role":29,"phone":25,"phoneExt":30,"email":31},{"type":53,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"SPONSOR_INVESTIGATOR","Stuart Mazzone","Professor",[57,60,62],{"name":58,"class":59},"Merck Sharp & Dohme LLC","INDUSTRY",{"name":61,"class":6},"Melbourne Health",{"name":63,"class":6},"Monash University","100501743","early-phase-1-effect-of-gefapixant-on-cough-related-brain-activity-in-patients-with-chronic-cough-100501743",false,"NCT05813223","Effect of Gefapixant on Cough-related Brain Activity in Patients With Chronic Cough","The Effect of Acute and Prolonged Administration of Gefapixant on Cough-related Brain Activity in Patients With Chronic Cough","Inclusion Criteria:\n\n* Written informed consent to participate in the study. 18-65 years old; Male or female.\n* Non-smokers for at least 5 years and have no history of neurological disease or any recent history (over 8 weeks) of acute respiratory infections.\n* Presence of Refractory Chronic Cough (RCC) or Unexplained Chronic Cough (UCC) for ≥1 year, defined as cough unresponsive to treatment for underlying conditions including reflux disease, asthma and rhinitis.\n* Presence of cough symptoms as determined by a self-reported cough severity of ≥40mm on 10-point scale on screening.\n\nExclusion Criteria:\n\n* Current smokers or recreational drug users.\n* Women who are pregnant.\n* People with contraindications to MRI scanning (i.e. metal implants, claustrophobia).\n* Children and\u002For young people (ie. \\\u003C18 years).\n* People with an intellectual or mental impairment.\n* People highly dependent on medical care.\n* People in existing dependent or unequal relationships with any member of the research team.\n* People with known allergy to chili (very rare).\n* Non-English speakers (as English proficiency is required to accurately complete research tasks).","ALL","18 Years","65 Years",{"count":75,"type":76},31,"ESTIMATED","INTERVENTIONAL",[79],"EARLY_PHASE1","Recently, a new drug called Gefapixant passed phase III clinical trials for cough suppression in patients with chronic cough. The goal of this clinical trial is to investigate the effect of acute and prolonged administration of the drug Gefapixant on cough-related brain activity in patients with chronic cough. The main question it aims to answer is: does the mechanism of action of Gefapixant on the brainstem and brain circuits regulating cough differ between acute and prolonged therapy in people with chronic cough?\n\nParticipants have their brain activity and their sensitivity to cough-inducing substances measured as well as complete questionnaires about their cough before and while taking daily Gefapixant.",[82],"Chronic Cough",[84,85,86,87,88],"functional brain imaging","ATP","Capsaicin","Refractory chronic cough","Mechanism of Disease","2024-05-07",{"date":91,"type":92},"2024-05-09","ACTUAL",{"date":94,"type":92},"2024-01-01",{"date":96,"type":76},"2026-06-30",{"name":54,"class":6},1]